

# Earnings of FY2019/3 1Q

## FUJIFILM Holdings Corporation

Aug. 9, 2018

### FORWARD-LOOKING STATEMENTS

Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties, and other factors. Accordingly, actual results may differ materially from those projected due to various factors.

### Performance Summary of FY2019/3 1Q

**FUJIFILM**

## Performance for FY2019/3 1Q : Main Points

**Both revenue and operating income proceeded according to the initial target.  
The revenue were flat, while the operating income increased  
compared to the previous fiscal year.**

Performance  
by segment

✓ Revenue  
Document decreased due to reduction of business of low-profit, low-end printers, while medical systems and electronic materials continued to increase

✓ Operating income  
Medical systems, electronic materials and document increased

Special note

- ✓ Structural reforms of document made good progress
- ✓ Irvine Scientific Sales Company and IS JAPAN became consolidated subsidiaries
- ✓ Buyback of the Company's shares of ¥100.0 billion decided

## Consolidated Performance for FY2019/3 1Q (Apr. 2018 – Jun. 2018)

(Billions of yen)

	FY2018/3 1Q (After amendment)*	FY2019/3 1Q	Change	Influence of exchange rate	Constant-currency basis
Revenue	571.5 100.0%	564.9 100.0%	(6.6) -1.2%	0.1	(6.7) -1.2%
Operating Income	34.1 6.0%	36.9 6.5%	2.8 +8.2%	2.0	0.8 +2.4%
Income before Income Taxes	57.6 10.1%	45.8 8.1%	(11.8) -20.5%	1.6	(13.4) -23.3%
Net Income Attributable to FUJIFILM Holdings	43.8 7.7%	28.3 5.0%	(15.5) -35.3%	1.1	(16.6) -37.8%
Net Income Attributable to FUJIFILM Holdings per Share	¥100.06	¥65.83	(¥34.23)		
Exchange Rates US\$/€/¥	¥111 ¥122	¥109 ¥130	(¥2) ¥8		

〈Other factors of change (YoY)〉 Operating income --- Raw material prices: -¥0.7 billion

\*The changes in the classification of the presentation of net periodic pension cost and net periodic postretirement benefit cost are applied retroactively, according to the update of U.S. accounting standards.

3

## Consolidated Revenue and Operating Income by Segment

(Billions of yen)

Revenue	1Q		Change	Influence of exchange rate	Constant-currency basis
	FY2018/3	FY2019/3			
Imaging Solutions	85.0	87.9	2.9 (+3.5%)	0.6	2.3 (+2.8%)
Healthcare	91.3	101.8	10.5 (+11.5%)	0.0	10.5 (+11.4%)
Healthcare & Material Solutions	230.0	235.9	5.9 (+2.6%)	0.0	5.9 (+2.6%)
Document Solutions	256.5	241.1	(15.4) (-6.0%)	(0.5)	(14.9) (-5.8%)
Total	571.5	564.9	(6.6) (-1.2%)	0.1	(6.7) (-1.2%)

Note: After elimination of intersegment transactions.

(Billions of yen)

Operating Income	1Q		Change	Influence of exchange rate	Constant-currency basis
	FY2018/3 (After amendment)	FY2019/3			
Imaging Solutions	12.5	12.2	(0.3) (-2.2%)	0.8	(1.1) (-8.8%)
Healthcare	(1.1)	0.8	1.9 -	0.0	1.9 -
Healthcare & Material Solutions	18.5	18.1	(0.4) (-2.2%)	0.1	(0.5) (-2.7%)
Document Solutions	10.4	14.9	4.5 (+43.4%)	1.1	3.4 (+33.2%)
Corporate Expenses & Eliminations	(7.3)	(8.3)	(1.0) -	0.0	(1.0) -
Total	34.1	36.9	2.8 (+8.2%)	2.0	0.8 (+2.4%)

4

## Summary by Operating Segment

### ■ Imaging Solutions

Revenue	YoY		Operating income	(Billions of yen)	
				YoY	
87.9	2.9	(+3.5%)	12.2	(0.3)	(-2.2%)

- In the photo imaging business, sales were strong in instant photo systems such as the *instax* series and *instax* films. *Wall Decor*, *Photobook* and other value-added printing businesses also expanded and contributed to the revenue.
- The sales volume of *instax* series totaled 1.75 million units. The targeted annual sales volume has been revised upward from 9.0 million to 10.0 million units.
- In the electronic imaging business, in addition to *FUJIFILM X-H1*, which was launched in March 2018, *FUJIFILM X-T100* was launched in June 2018. Sales of interchangeable lenses were solid.
- In the optical device business, sales increased, reflecting steady performance of various industrial-use lenses. 4K lenses for use in broadcasting are highly valued for their image quality, seeking to increase the market share with the diverse lineup of 8 models.

Revenue increased due to strong sales in all businesses, while operating income remained at the same level, due to upfront investment such as R&D and others.

5

## Summary by Operating Segment

### ■ Healthcare & Material Solutions

Revenue	YoY		Operating income	(Billions of yen)	
				YoY	
235.9	5.9	(+2.6%)	18.1	(0.4)	(-2.2%)

- In the healthcare business field, medical systems business enjoyed brisk sales in such business areas as In-vitro Diagnostic systems, X-ray imaging diagnostic and endoscope. In the pharmaceutical business, *Avigan Tablet*, the anti-influenza drug, was supplied to a national stockpile in Japan. Fujifilm decided to form FUJIFILM Toyama Chemical as of October 2018 to accelerate the development of new diagnostic and therapeutic drugs. In the bio CDMO business, the expansion of facility contributed to contract manufacturing and development of biopharmaceuticals.
- As for the highly functional materials business field, though the overall sales decreased mainly due to the decline in demand for WV film, sales of products related to touch-panels were strong in the display materials business. In the electronic materials business, sales increased mainly for advanced products of photo resists and peripheral materials related to photolithography.
- In the recording media business, sales decreased due to the inventory adjustment of magnetic tape for data storage and other factors. In the graphic systems business, sales decreased due to a decline in total demand for graphic arts film and CTP plates. In the inkjet business, favorable sales were seen in industrial inkjet printheads, mainly in the ceramics field.

Revenue increased due to strong sales in the medical systems and electronic materials. Operating income was in line with the previous fiscal year due to such factors as increased raw material cost.

6

## Summary by Operating Segment

### Document Solutions

Revenue	YoY		Operating income	(Billions of yen) YoY	
	Mar.18	Mar.17		Mar.18	Mar.17
241.1	(15.4)	(-6.0%)	14.9	4.5	(+43.4%)

- In the office products business, overall sales volume increased from the previous fiscal year, due to strong sales of a newly developed small-sized multifunction device in China and increased export shipments of new products to the U.S. and Europe.  
In the office printer business, sales volume decreased due to reduction of business of low-end printers.
- In the production services business, though the overall number of sales units decreased mainly in the low-mid speed model, strong sales were seen for a high-speed and high-quality on-demand color production printer, launched in the U.S. and Europe after it was released in November 2017 in Japan and Asia, .
- In the solutions and services business, though the sales of business-specific solutions and existing BPO contracts showed steady growth, overall sales decreased due to a change in an accounting method for recognizing revenue from purchased products.

Revenue declined despite strong sales in China and export to Europe and the U.S. due to reduction of low-profit, low-end printer business and others. Operating income increased due to the benefit of the structural reforms and improvement of profitability.

7

## Consolidated Balance Sheet

(Billions of yen)


	Mar.17	Mar.18	Jun. 18	Change from Mar.18		Mar.17	Mar.18	Jun. 18	Change from Mar.18
Cash and cash equivalents	876.0	768.2	723.9	(44.3)	Short-term and long-term debt	558.8	454.2	452.8	(1.4)
Notes and accounts receivable	635.8	619.1	561.8	(57.3)	Notes and accounts payable	257.9	248.5	238.3	(10.2)
Inventories	339.2	361.3	393.9	32.6	Other liabilities	448.4	491.5	479.6	(11.9)
Other current assets	183.8	112.2	136.9	24.7	Total liabilities	1,265.1	1,194.2	1,170.7	(23.5)
Total current assets	2,034.8	1,860.8	1,816.5	(44.3)	Total FUJIFILM Holdings shareholders' equity	2,043.6	2,079.1	2,117.9	38.8
Property, plant and equipment	520.6	537.5	532.2	(5.3)	Noncontrolling interests	224.5	219.6	219.4	(0.2)
Goodwill, net	499.8	591.6	676.9	85.3	Total equity	2,268.1	2,298.7	2,337.3	38.6
Investment securities and other	478.0	503.0	482.4	(20.6)	Total liabilities and equity	3,533.2	3,492.9	3,508.0	15.1
Total noncurrent assets	1,498.4	1,632.1	1,691.5	59.4	(yen)				
Total assets	3,533.2	3,492.9	3,508.0	15.1	Exchange Rates	Mar.17	Mar.18	Jun. 18	Change from Mar.18
					US\$/¥	¥112	¥106	¥111	¥5
					€/¥	¥120	¥131	¥128	(¥3)

8

# Cash Flows

- C/F from operating activities
- C/F from investing activities
- Free cash flows (without acquisitions of businesses)

(Billions of yen)



(Billions of yen)

	FY2017/3 1Q	FY2018/3 1Q	FY2019/3 1Q
Net income	14.9	47.6	31.3
Depreciation & amortization	30.5	30.7	31.3
Change in notes and accounts receivable	76.7	74.5	58.5
Change in inventories	(19.8)	(30.6)	(29.3)
Change in notes and accounts payable-trade	(1.7)	(21.2)	(7.5)
Others	4.1	(7.6)	2.7
C/F from operating activities	104.7	93.4	87.0
Capital expenditure	(20.3)	(13.4)	(14.8)
Purchases of software	(3.2)	(3.3)	(3.8)
Sales and purchases of marketable and investment securities	7.8	(7.2)	(0.2)
Acquisitions of businesses	(0.3)	(125.7)	(84.4)
Others	(8.4)	1.3	(3.2)
C/F from investing activities	(24.4)	(148.3)	(106.4)
Free cash flows	80.3	(54.9)	(19.4)

Free cash flows without acquisitions of businesses and others *	72.8	78.0	65.2
---	------	------	------

\* After deduction of acquisition of business, sales and purchases of marketable and investment securities .

9

## Earnings for FY2019/3 1Q

# Structural Reforms of Fuji Xerox

## Structural Reforms of Fuji Xerox

Structural reforms in FY2019/3 1Q progressed as planned.  
Business base to be established in new growth areas.

	FY2018/3 Actual	FY2019/3 Forecast	From FY2020/3 Forecast
Structural reform expenses etc.	¥70.0 billion (Full year)	¥25.0 billion	¥6.0 billion
Benefit	-	¥27.0 billion	¥55.0 billion

FY2019/3	1Q (actual)	Full year (forecast)
Structural reform expenses etc.	¥3.3 billion	¥25.0 billion
Benefit	¥1.0 billion	¥27.0 billion

Earnings of FY2019/3 1Q

## Forecast for FY2019/3

## Consolidated Financial Forecast for FY2019/3 (as of Aug. 9, 2018)

(Billions of yen)

	FY2018/3 (After amendment)	FY2019/3	Change from previous year
Revenue	2,433.4 100.0%	2,510.0 100.0%	76.6 +3.1%
Operating Income	123.3 5.1%	200.0 8.0%	76.7 +62.2%
Income before Income Taxes	197.8 8.1%	205.0 8.2%	7.2 +3.6%
Net Income Attributable to FUJIFILM Holdings	140.7 5.8%	130.0 5.2%	(10.7) -7.6%
Net Income Attributable to FUJIFILM Holdings per Share	¥322.62	¥302.16	(¥20.46)
ROE	6.8%	6.2%	-0.6%
Exchange Rates US\$/¥	¥111	¥110	(¥1)
€/\$	¥130	¥130	-
Silver Price (/kg)	¥61,000	¥62,000	¥1,000

	FY2018/3	FY2019/3
Operating income excluding one-time expenses	193.3	225.0
One-time expenses including structural reform expenses	(70.0)	(25.0)
Operating income	123.3	200.0

Note: Exchange rate sensitivity for operating income (FY2019/3 full year) US\$/¥: ¥0.8 billion €/¥: ¥0.8 billion


13

## Earnings for FY2019/3 1Q

# Appendix

14

## Analysis of Operating Income Change (Against FY2018/3 1Q)



15

## Earnings for FY2019/3 1Q

### ■ Imaging Solutions

(Billions of yen)

Revenue	FY2018/3		FY2019/3		1Q Change		Constant-currency basis	
	Revenue	Operating Margin	Revenue	Operating Margin	Revenue	Operating Margin	Revenue	Operating Margin
Photo Imaging	53.8	[14.7%]	55.8	[13.9%]	2.0	(+3.8%)	1.8	(+3.4%)
Electronic Imaging	22.3		22.8		0.5	(+2.2%)	0.2	(+0.9%)
Optical Devices	8.9		9.3		0.4	(+5.0%)	0.3	(+4.4%)
Optical Device & Electronic Imaging Products	31.2		32.1		0.9	(+3.0%)	0.5	(+1.9%)
Total	85.0		87.9		2.9	(+3.5%)	2.3	(+2.8%)

Note: After elimination of intersegment transactions.


Operating Income [Operating Margin]	FY2018/3		FY2019/3		1Q Change		Constant-currency basis	
	Revenue	Operating Margin	Revenue	Operating Margin	Revenue	Operating Margin	Revenue	Operating Margin
Imaging Solutions	12.5	[14.7%]	12.2	[13.9%]	(0.3)	(-2.2%)	(1.1)	(-8.8%)

16



# Change in Quarterly Earnings by Segment

## Imaging Solutions



# Earnings for FY2019/3 1Q

## Healthcare & Material Solutions

(Billions of yen)


Revenue	1Q					
	FY2018/3	FY2019/3	Change		Constant-currency basis	
Healthcare	91.3	101.8	10.5	(+11.5%)	10.5	(+11.4%)
Display Materials	24.3	23.0	(1.3)	(-5.5%)	(1.3)	(-5.6%)
Industrial Products Electronic Materials Fine Chemical	42.1	43.6	1.5	(+3.4%)	1.7	(+4.0%)
Highly Functional Materials	66.4	66.6	0.2	(+0.1%)	0.4	(+0.5%)
Recording Media	11.6	9.3	(2.3)	(-19.2%)	(2.2)	(-18.3%)
Graphic Systems/Inkjet	60.6	57.9	(2.7)	(-4.4%)	(3.0)	(-4.8%)
Others	0.1	0.3	0.2		0.2	
<b>Total</b>	<b>230.0</b>	<b>235.9</b>	<b>5.9</b>	<b>(+2.6%)</b>	<b>5.9</b>	<b>(+2.6%)</b>

Note: After elimination of intersegment transactions.

Operating Income [Operating Margin]	1Q					
	FY2018/3 (After amendment)	FY2019/3	Change		Constant-currency basis	
Healthcare	(1.1)	0.8	1.9	-	1.9	-
	[-1.2%]	[0.8%]				
Healthcare & Material Solutions	18.5	18.1	(0.4)	(-2.2%)	(0.5)	(-2.7%)
	[8.0%]	[7.7%]				

# Change in Quarterly Earnings by Segment

## Healthcare & Material Solutions



# Earnings for FY2019/3 1Q

## Document Solutions

(Billions of yen)


Revenue	1Q					
	FY2018/3	FY2019/3	Change		Constant-currency basis	
Office Printers	38.8	30.1	(8.7)	(-22.5%)	(8.4)	(-21.7%)
Office Products & Printers	152.1	139.7	(12.4)	(-8.2%)	(12.1)	(-8.0%)
Production Services	32.0	29.2	(2.8)	(-8.9%)	(2.8)	(-9.0%)
Solutions & Services	59.6	57.9	(1.7)	(-2.9%)	(1.5)	(-2.5%)
Others	12.8	14.3	1.5		1.5	
Total	256.5	241.1	(15.4)	(-6.0%)	(14.9)	(-5.8%)

Note: After elimination of intersegment transactions.

Operating Income [Operating Margin]	1Q					
	FY2018/3 (After amendment)	FY2019/3	Change		Constant-currency basis	
Document Solutions	10.4 [4.1%]	14.9 [6.2%]	4.5	(+43.4%)	3.4	(+33.2%)

## Change in Quarterly Earnings by Segment

### Document Solutions





## Revenue by Destination

(Billions of yen)

	FY2018/3 1Q		FY2019/3 1Q		Change	
	Ratio (%)		Ratio (%)			
Domestic	40.5%	231.5	40.7%	229.9	(1.6)	(-0.7%)
The Americas	19.8%	113.1	19.0%	107.6	(5.5)	(-4.9%)
Europe	12.0%	68.4	12.7%	71.8	3.4	(+4.9%)
China	12.4%	71.0	12.9%	73.1	2.1	(+2.8%)
Asia and others	27.7%	158.5	27.6%	155.6	(2.9)	(-1.9%)
Overseas	59.5%	340.0	59.3%	335.0	(5.0)	(-1.5%)
Consolidated total	100.0%	571.5	100.0%	564.9	(6.6)	(-1.2%)

# Capital Expenditure , Depreciation & Amortization

Capital Expenditure (1Q)



(Billions of yen)

	1Q			Full year		
	FY 2017/3	FY 2018/3	FY 2019/3	FY 2017/3	FY 2018/3	FY2019/3 (forecast)
Imaging	2.1	1.7	3.0	10.3	9.4	
Healthcare & Material	9.6	7.5	7.3	40.1	42.7	
Document	4.3	4.3	2.0	20.0	13.8	
Corporate	0.1	0.2	0.1	1.4	1.6	
Capex *	16.1	13.7	12.4	71.8	67.5	80.0
Imaging	2.9	3.3	3.4	11.1	13.3	
Healthcare & Material	12.6	14.0	14.3	49.1	57.5	
Document	14.5	12.8	13.0	55.3	54.7	
Corporate	0.5	0.6	0.6	2.1	2.1	
Depreciation & Amortization	30.5	30.7	31.3	117.6	127.6	119.0
Depreciation *	14.2	16.2	16.7	58.9	66.5	

- Imaging
- Healthcare & Material
- Document
- Corporate

\*Note: Figures do not include amounts for rental equipment handled by the Document Solutions segment and others.

# R&D Expenses, SG&A Expenses

R&D Expenses (1Q)



(Billions of yen)

	1Q		Full year	
	FY2018/3	FY2019/3	FY2018/3	FY2019/3 (forecast)
Imaging	1.7	2.5	9.0	
Healthcare & Material	15.9	17.8	70.0	
Document	14.1	13.8	63.5	
Corporate	5.9	6.0	25.4	
R&D Expenses	37.6	40.1	167.9	161.0
<ratio to revenue>	6.6%	7.1%	6.9%	6.4%
SG&A Expenses	159.1	158.7	677.8	
<ratio to revenue>	27.8%	28.1%	27.9%	

- Imaging
- Healthcare & Material
- Document
- Corporate

## Exchange rates, Raw Material Prices, and Number of Employees

## Exchange Rates

(yen)

	FY2018/3					FY2019/3	
	1Q	2Q	3Q	4Q	Full year	1Q	Full year (forecast)
US\$/¥	111	111	113	108	111	109	110
€/¥	122	130	133	133	130	130	130

## Raw Material Prices (Average)

(¥1,000/kg)

	FY2018/3					FY2019/3	
	1Q	2Q	3Q	4Q	Full year	1Q	Full year (forecast)
Silver	63	60	61	58	61	58	62

## Number of Employees

	2017.Jun	2017.Sep	2017.Dec	2018.Mar	2018.Jun
Consolidated Total	80,672	80,315	80,067	77,739	77,060

25

## Amendment to FY2018/3 Financial Results (Operating Income) Accompanying the Change in Accounting Method

(Billions of yen)

Operating Income	FY 2018/3 (Before amendment)				
	1Q	2Q	3Q	4Q	Full Year
Imaging Solutions	12.6	11.3	26.1	6.0	56.0
Healthcare	(0.8)	2.7	5.5	13.3	20.7
Healthcare & Material Solutions	18.9	19.1	23.2	31.6	92.8
Document Solutions	11.7	17.4	11.4	(26.5)	14.0
Corporate Expenses & Eliminations	(7.4)	(7.7)	(8.0)	(9.0)	(32.1)
Total	35.8	40.1	52.7	2.1	130.7

(Billions of yen)

Operating Income	FY 2018/3 (After amendment)									
	1Q	Change	2Q	Change	3Q	Change	4Q	Change	Full Year	Change
Imaging Solutions	12.5	(0.1)	11.2	(0.1)	26.1	0.0	5.9	(0.1)	55.7	(0.3)
Healthcare	(1.1)	(0.3)	2.4	(0.3)	5.2	(0.3)	13.3	0.0	19.8	(0.9)
Healthcare & Material Solutions	18.5	(0.4)	18.7	(0.4)	22.6	(0.6)	31.6	0.0	91.4	(1.4)
Document Solutions	10.4	(1.3)	16.1	(1.3)	10.1	(1.3)	(28.2)	(1.7)	8.4	(5.6)
Corporate Expenses & Eliminations	(7.3)	0.1	(7.8)	(0.1)	(8.0)	0.0	(9.1)	(0.1)	(32.2)	(0.1)
Total	34.1	(1.7)	38.2	(1.9)	50.8	(1.9)	0.2	(1.9)	123.3	(7.4)

26

## Consolidated Financial Forecast for FY2019/3 (as of Aug. 9, 2018)

(Billions of yen)

	FY2018/3 (After amendment)	FY2019/3 1H	FY2019/3 2H	FY2019/3	Change from previous year
Revenue	2,433.4 100.0%	1,190.0 100.0%	1,320.0 100.0%	2,510.0 100.0%	76.6 +3.1%
Operating Income	123.3 5.1%	75.0 6.3%	125.0 9.5%	200.0 8.0%	76.7 +62.2%
Income before Income Taxes	197.8 8.1%	79.0 6.6%	126.0 9.5%	205.0 8.2%	7.2 +3.6%
Net Income Attributable to FUJIFILM Holdings	140.7 5.8%	46.0 3.9%	84.0 6.4%	130.0 5.2%	(10.7) -7.6%

## Consolidated Financial Forecast for FY2019/3 by Segment (as of Aug. 9, 2018)

(Billions of yen)

Revenue	FY2018/3 (After amendment)	FY2019/3	Change from previous year	
Imaging Solutions	383.0	400.0	17.0	(+4.4%)
Healthcare	443.0	475.0	32.0	(+7.2%)
Healthcare & Material Solutions	1,002.6	1,060.0	57.4	(+5.7%)
Document Solutions	1,047.8	1,050.0	2.2	(+0.2%)
Total	2,433.4	2,510.0	76.6	(+3.1%)

Note: After elimination of intersegment transaction.

Operating Income	FY2018/3 (After amendment)	FY2019/3	Change from previous year	
Imaging Solutions	55.7	60.0	4.3	(+7.7%)
Healthcare	19.8	21.0	1.2	(+6.1%)
Healthcare & Material Solutions	91.4	91.0	(0.4)	(-0.4%)
Document Solutions	8.4	82.0	73.6	(9.8 times)
Corporate Expenses & Eliminations	(32.2)	(33.0)	(0.8)	
Total	123.3	200.0	76.7	(+62.2%)

	FY2018/3	FY2019/3
Operating income excluding one-time expenses	78.4	107.0
One-time expenses including structural reform expenses	(70.0)	(25.0)
Operating income	8.4	82.0

## Shareholder Returns

### Dividend

Dividend for FY2019/3 is planned at ¥80 per share, increased by ¥5 from the previous fiscal year. The dividend increase is expected for 9 consecutive years.



## Pipeline (as of Aug. 9, 2018)

Development code	Therapeutic category	Formulation	Region	Development stage
T-705	Anti-influenza drug	Oral	Japan	Approved
			U.S.A.	P III
	Severe fever with thrombocytopenia syndrome virus drug	Oral	Japan	P III
T-3811	Quinolone synthetic antibacterial drug	Oral	China	Submitted an application for permission
T-2307	Antifungal drug	Injection	U.S.A.	P I
T-817MA	Alzheimer's disease drug	Oral	U.S.A.	P II
			Japan	P II
T-4288	New fluoroketolide antibacterial drug	Oral	Japan	P III
ITK-1	Castration-resistant prostate cancer drug	Injection	Japan	P III
FF-10501	Myelodysplastic syndrome drug	Oral	Japan	P I
			U.S.A.	P II
FF-10502	Advanced/recurrent solid cancer drug	Injection	U.S.A.	P II
FF-21101	Bio Advanced/recurrent solid cancer drug (Armed antibody)	Injection	U.S.A.	P I
F-1311	Diagnostic drug for prostate cancer (Radiopharmaceuticals)	Injection	Japan	P II
FF-10101	Acute Myeloid Leukemia (AML) drug	Oral	U.S.A.	P I
F-1515	Anti-tumor (neuroendocrine tumors) drug (Radiopharmaceuticals)	injection	Japan	P I
FF-10832	Advanced solid cancer drug (Gemcitabine liposome)	Injection	U.S.A.	P I
F-1614	Anti-tumor (pheochromocytoma) drug (Radiopharmaceuticals)	Injection	Japan	P II

Note: FKB327 (a biosimilar of adalimumab) of FUJIFILM KYOWA KIRIN Biologics (FKB), an equity method affiliated company, is filed in EU.

FKB238 (a biosimilar of bevacizumab) of JV between FKB and AstraZeneca is under phase III clinical trial in U.S.A., Europe, and others.

# Appendix

## [FUJIFILM Holdings – Investor Relations](#)

<http://www.fujifilmholdings.com/en/investors/index.html>

## [FUJIFILM Holdings Integrated Report 2017](#)

[http://www.fujifilmholdings.com/en/investors/ir\\_library/integrated\\_reports/index.html](http://www.fujifilmholdings.com/en/investors/ir_library/integrated_reports/index.html)

## [IR Events Materials](#)

[http://www.fujifilmholdings.com/en/investors/ir\\_events/business\\_presentations/index.html](http://www.fujifilmholdings.com/en/investors/ir_events/business_presentations/index.html)

### · Business presentation materials

- Dec. 2016 Business Presentation for Pharmaceuticals/Regenerative Medicine Business
- Mar. 2017 Business Presentation for Electronic Materials Business
- Mar. 2018 Business Presentation for Imaging Solutions Businesses

## [What Kind of Company is Fujifilm?](#)

<http://www.fujifilmholdings.com/en/investors/guidance/index.html>

# FUJIFILM

## Value from Innovation

At Fujifilm, we are continuously innovating — creating new technologies, products and services that inspire and excite people everywhere.

Our goal is to empower the potential and expand the horizons of tomorrow's businesses and lifestyles.

### **FUJIFILM Holdings Corporation**

Corporate Communication Office, Corporate Planning Div.

<http://www.fujifilmholdings.com/en/index.html>